NEW YORK (GenomeWeb) – Biodesix said today that its has received a positive coverage decision from Aetna for its VeriStrat test for guiding therapy in patients with non-small cell lung cancer (NSCLC).

According to Biodesix, Aetna has deemed VeriStrat, which uses MALDI mass spec-based proteomic signatures to identify patients likely to respond to treatment with EGFR inhibitors, medically necessary for patients with advanced NSCLC whose tumors were without EGFR and anaplastic lymphoma kinase mutations.

Aetna has approximately 46 million members in the US.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.

An opinion piece at Bloomberg discusses China's stance on genomic research.

Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.

Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.